Sanofi (SNY)
| Market Cap | 97.03B -15.7% |
| Revenue (ttm) | 55.89B +7.0% |
| Net Income | 4.52B -56.6% |
| EPS | 1.86 -55.6% |
| Shares Out | 1.20B |
| PE Ratio | 21.46 |
| Forward PE | 8.09 |
| Dividend | $1.76 (4.30%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 1,496,444 |
| Open | 41.35 |
| Previous Close | 40.74 |
| Day's Range | 40.96 - 41.38 |
| 52-Week Range | 40.40 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 53.72 (+30.56%) |
| Earnings Date | Oct 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 nov... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $53.72, which is an increase of 30.56% from the latest price.
News
Sanofi SA at Bank of America Global Healthcare Conference Transcript
Sanofi SA at Bank of America Global Healthcare Conference Transcript
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
Sanofi NASDAQ: SNY is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global...
Sanofi Transcript: Bank of America Global Healthcare Conference
Leadership changes have driven a renewed focus on I&I, rare diseases, and vaccines, with rigorous portfolio review and a balanced approach to internal and external innovation. Key pipeline assets are advancing under heightened scrutiny, and ongoing alliances and platform deals aim to strengthen research productivity and future output.
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the compa...
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early pa...
Sanofi's C$925M Facility To Support 2027-28 Flu Vaccine Season
(RTTNews) - Sanofi (SNY) announced the inauguration of the Charles Best Building, a new influenza vaccine manufacturing facility in Toronto, Canada, following a C$925 million investment to expand the ...
Sanofi inaugurates Canadian flu vaccine faclity
Sanofi (SNY) inaugurated the Charles Best Building, a flu vaccine manufacturing facility that will manufacture Sanofi’s Fluzone High-Dose influenza vaccine. This new manufacturing facility also offers...
Sanofi SA at Morgan Stanley Global Healthcare Conference Transcript
Sanofi SA at Morgan Stanley Global Healthcare Conference Transcript
Sanofi Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Management is focused on sustaining specialty care growth, expanding core areas, and balancing early- and late-stage deal-making to address future revenue needs. Dupixent's growth is driven by low biopenetration and lifecycle management, while operational and R&D rigor underpin pipeline execution.
Sanofi, Cheplapharm enter strategic partnership
Sanofi (SNY) and Cheplapharm announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing ...
Sanofi To Receive 26.4% Stake In Cheplapharm For Mature Medicines
(RTTNews) - Sanofi (SNY, SAN.PA), a healthcare company, on Monday announced an agreement with Cheplapharm to create a strategic partnership for its mature medicines portfolio.
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Sanofi and Cheplaphar m to create new strategic partnership i n mature medicines
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-ter...
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Analysts Think These Stocks Could More Than Double in ValueNovavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model...
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
MORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026 /PRNewswire/ -- Sanofi and USA Pickleball are teaming up to launch "Serve Up Protection," a campaign to educate older adults about COVID-19 and N...
Sanofi price target raised to EUR 100 from EUR 95 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on Sanofi (SNY) to EUR 100 from EUR 95 and keeps a Buy rating on the shares. The firm adjusted targets…
Sanofi initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Sanofi (SNY) with a Sector Perform rating and EUR 80 price target Near-term challenges include limited catalysts, Dupixent’s patent cliff, and skepticism about delive...
Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate families about protection against a serious respiratory syncytial virus (RSV) lung infection BEYFORTUS...
Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season
(RTTNews) - Novavax, Inc. (NVAX) on Friday announced that its partners, Sanofi and Takeda, have received regulatory approvals for XFG-adapted Nuvaxovid COVID-19 vaccine for the 2026-2027 vaccination s...
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.
Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley
Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Sanofi (SNY) to EUR 82 from EUR 86 and keeps an Equal Weight rating on the shares. Published first…
Sanofi facing shortages of two drugs for Pompe disease, STAT reports
Sanofi (SNY) is facing shortages of Myozyme and Nexviazyme for Pompe disease after manufacturing and quality-control issues at its Waterford facility, which was cited by the FDA in June for…
Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has a...